scholarly journals Mesto strikturoplastike u lecenju Crohn-ove bolesti

2002 ◽  
Vol 49 (1) ◽  
pp. 9-14
Author(s):  
Milos Popovic ◽  
Milorad Petrovic ◽  
Slavko Matic ◽  
Aleksandar Milovanovic
Keyword(s):  
Crohn’S Disease ◽  
Surgical Treatment ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Operative Technique ◽  
Surgical Procedure ◽  
Minimal Invasive ◽  
Functional Disturbances ◽  
Morbid Process

Crohn's disease is pandigestive disease of unknown ae-thiology, with tendency to recurrences. Until now it is impossible to heal this disease either by medical or surgical treatment. All unfavorable consequences of this disease are result of inadequate treatment of complications which are leading to systemic weakening, with further progression of morbid process. Therefore, the principle of timely and minimal invasive surgical procedure has been generally adopted. Introduced in eighties, strictureplasty is a procedure of such characteristics. During the period 1980-2001 this method was used in 1/3 of 126 patients with Crohn's disease. There were 79 strictureplaties performed, 9 long and 70 short. Out of these 42, 12(28,6%) were postoperative recurrences, and there was one case of duodenal strictureplatsty. Postoperative small bowel fistulae were not observed, and there was no mortality in this group. During the follow up period of at least 5 years, in only two cases (4,76%) some functional disturbances of digestive functions were observed, without indications for reoperation. In this article indications and details of operative technique are discussed.

scholarly journals P629 Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-up

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S427-S428
Author(s):  
S D'Ugo ◽  
F Romano ◽  
G Bagaglini ◽  
L Fazzolari ◽  
B Sensi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Surgical Treatment ◽  
Crohn's Disease

scholarly journals Postheparin plasma diamine oxidase values in the follow up of patients with small bowel Crohn's disease.

Gut ◽  
1991 ◽  
Vol 32 (8) ◽  
pp. 932-935 ◽  
Author(s):  
L D'Agostino ◽  
S Pignata ◽  
B Daniele ◽  
M Visconti ◽  
C Ferraro ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Diamine Oxidase

Colon Adenocarcinoma Metastasis Through Ileocolic Fistula to Small Bowel in the Setting of Crohn’s Disease

2021 ◽  
Author(s):  
Michael Tseng ◽  
Taseen Ahmed Syed ◽  
Patricija Zot ◽  
Ravi Vachhani
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Unusual Case ◽  
Colon Adenocarcinoma ◽  
Fistula Tract ◽  
Gastrointestinal Fistula ◽  
The Past ◽  
Pathology Reports

Abstract Purpose: Patients with Crohn’s disease (CD) are at higher risk of developing colorectal cancer (CRC) and gastrointestinal fistula. We report an unusual case of sigmoid colon adenocarcinoma in a CD patient that metastasized to the small bowel through an ileocolic fistula tract.Methods: This case report was written after patient was seen in the clinic and reviewing overall hospitalization including clinically relevant data including imaging and pathology reports associated to our focus and presentation. Prior cases of metastatic CRC via fistula tract were reviewed and compared as well. Results: We described an unprecedented case of a sigmoid adenocarcinoma metastasized to ileum via ileal-sigmoid fistula. Patient received surgical treatment and systemic chemotherapy and currently in remission. Conclusion: CD is associated with a higher risk of fistula development. Few cases in the past described CRC metastasized within the gastrointestinal tract through a fistula. Intriguingly in our case, sigmoid adenocarcinoma developed and further metastasized to the ileum via the ileal-sigmoid fistula in the setting of CD. In addition to presenting a unique pathological phenomenon in these patients, this case raises awareness of the importance of regular follow-up and early initiation of IBD therapies.

scholarly journals Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

Gut ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Yoram Bouhnik ◽  
Franck Carbonnel ◽  
David Laharie ◽  
Carmen Stefanescu ◽  
Xavier Hébuterne ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Bowel Resection ◽  
Prognostic Score ◽  
Small Bowel Stricture ◽  
Observational Cohort ◽  
Prognosis Group ◽  
Bowel Stricture

ObjectiveThe efficacy of anti-tumour necrosis factors (anti-TNFs) in patients with Crohn's disease (CD) and symptomatic small bowel stricture (SSBS) is controversial. The aim of this study was to estimate the efficacy of adalimumab in these patients and to identify the factors predicting success.DesignWe performed a multicentre, prospective, observational cohort study in patients with CD and SSBS. The included patients underwent magnetic resonance enterography at baseline and subsequently received adalimumab. The primary endpoint was success at week 24, defined as adalimumab continuation without prohibited treatment (corticosteroids after the eight week following inclusion, other anti-TNFs), endoscopic dilation or bowel resection. The baseline factors independently associated with success were identified using a logistic regression model, leading to a simple prognostic score. Secondary endpoints were prolonged success after week 24 (still on adalimumab, without dilation nor surgery) and time to bowel resection in the whole cohort.ResultsFrom January 2010 to December 2011, 105 patients were screened and 97 were included. At week 24, 62/97 (64%) patients had achieved success. The prognostic score defined a good prognosis group with 43/49 successes, an intermediate prognosis group with 17/28 successes and a poor prognosis group with 1/16 successes. After a median follow-up time of 3.8 years, 45.7%±6.6% (proportion±SE) of patients who were in success at week 24 (ie, 29% of the whole cohort) were still in prolonged success at 4 years. Among the whole cohort, 50.7%±5.3% of patients did not undergo bowel resection 4 years after inclusion.ConclusionsA successful response to adalimumab was observed in about two-thirds of CD patients with SSBS and was prolonged in nearly half of them till the end of follow-up. More than half of the patients were free of surgery 4 years after treatment initiation.Clinical Trial registration numberNCT01183403; Results.

Quantification, validation, and follow-up of small bowel motility in Crohn's disease

2015 ◽  
Author(s):  
Juan J. Cerrolaza ◽  
Jennifer Q. Peng ◽  
Nabile M. Safdar ◽  
Laurie Conklin ◽  
Raymond Sze ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Bowel Motility ◽  
Small Bowel Motility

scholarly journals Development of significant disease in a cohort of patients with non-specific enteritis on capsule endoscopy. Clinical suspicion and a high base line Lewis score are predictive of Crohn’s disease.

2020 ◽  
Author(s):  
Sandeep Sihag ◽  
Brandon Tan ◽  
Serhiy Semenov ◽  
Mohd Syafiq Ismail ◽  
Barbara Ryan ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Capsule Endoscopy ◽  
Gastrointestinal Disease ◽  
Female Gender ◽  
Clinical Suspicion ◽  
Base Line ◽  
Significant Disease

Abstract Background: As with isolated ileitis the findings of nonspecific small bowel enteritis (NSE) on capsule endoscopy (CE) poses a clinical challenge. There is lack of available evidence to help clinicians to predict significant disease and long-term prognosis. Methods: We aimed to define the natural history of NSE in an Irish cohort. Patients with a finding of NSE were identified from a database. Subsequent investigations, treatments and diagnosis were recorded. Patients were grouped based on ultimate diagnosis: Crohn’s disease (CD), Irritable bowel syndrome (IBS), NSAIDs enteritis (NSAIDs), persistent NSE and no significant disease (NAD). Results: 88 patients, 46 (52%) male, mean age 52 +- 17.8 years were included with a mean follow up of 23 +- 19 months. The ultimate diagnoses were NAD=43 (49%), CD =17 (19%), IBS =14 (16%), NSAIDs =12 (14%) and persistent NSE=2 (2%). Significantly, more patients diagnosed with CD on follow up were referred with suspected CD. CD= 14/17 (82%) vs 13/57 (23%), p < 0.001. While a diagnosis of CD was associated with a positive baseline Lewis score (>135); 11/17 (65%) CD versus 16/ 71 (23%). Female gender was associated with an ultimate diagnosis of IBS (OR 5, p <0.02). Older age was associated with NSAIDs enteritis, while more subjects without significant gastrointestinal disease were anemic on presentation. Conclusion: The majority (49%) of NSE patients do not develop significant small bowel disease. CD occurred in 19% of NSE patients on follow up. Clinical suspicion and capsule severity are predictive of Crohn’s disease on initial CE.

Sign in / Sign up

Export Citation Format

Share Document